Biohaven initiates pivotal trial of novel investigational drug for treatment of migraine

Biohaven initiated a pivotal phase 2 trial evaluating bhv-2100 in the acute treatment of migraine bhv-2100 is a potential first-in-class, potent, orally administered transient receptor potential melastatin-3 (trpm3) antagonist— a novel, highly selective, and non-opioid investigational treatment being developed for migraine and other pain disorders despite recent treatment advances, migraine remains a leading cause of disability and burden, impacting 40 million people in the us and 1 billion world-wide new haven, conn. , sept. 30, 2024 /prnewswire/ -- biohaven ltd.
BHVN Ratings Summary
BHVN Quant Ranking